CD33 and acute myeloid leukemia: In another study, Carvalho et al. encapsulated ABT-737 and Purvalanol into PEGylated PLGA nanoparticles, which were subsequently conjugated to gemtuzumab for targeting the CD33 transmembrane protein in pediatric acute myeloid leukemia (AML) [82].